A Multicenter, Single-arm, Open-label, Long-term Follow-up Safety Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms SOMBRERO
- Sponsors Actelion Pharmaceuticals
- 27 Mar 2024 Status changed from active, no longer recruiting to completed.
- 11 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2021 Planned End Date changed from 25 Aug 2028 to 18 Sep 2028.